Second Genome

Second Genome is a leading microbiome company that uses big data/metadata sets, proprietary algorithms, bioinformatics, 'omics technologies, machine learning, cell-based functional screens and micro/biological technologies to mine novel therapeutics from the human microbiome to solve unmet medical needs. It has established a therapeutic pipeline for gastrointestinal disorders, metabolic disease, immunological disorders and cancer. The technology platform can be leveraged for health and wellness, agriculture, animal, environment and industrial applications. In the 2H2016, it raised a $51 million Series B, led by pharma investors including Pfizer Venture Investments, Roche Venture Fund and SR One Venture Partners.